Stifel Maintains Inozyme Pharma(INZY.US) With Buy Rating, Maintains Target Price $16
Inozyme Pharma Initiated at Buy by Stifel
Stifel Initiates Inozyme Pharma(INZY.US) With Buy Rating, Announces Target Price $16
Jefferies Initiates Inozyme Pharma(INZY.US) With Buy Rating, Announces Target Price $17
Inozyme Pharma: A Buy Rating With Multi-Billion Dollar Market Potential and Upcoming Catalysts
Analysts Offer Insights on Healthcare Companies: Tango Therapeutics (TNGX), Inozyme Pharma (INZY) and Foghorn Therapeutics (FHTX)
TD Cowen Maintains Inozyme Pharma(INZY.US) With Buy Rating
Needham Reiterates Buy on Inozyme Pharma, Maintains $23 Price Target
Inozyme Pharma: A Buy Rating Backed by Clinical Trials and Market Potential
Needham Maintains Inozyme Pharma(INZY.US) With Buy Rating, Maintains Target Price $23
Analysts' Top Healthcare Picks: Inozyme Pharma (INZY), Glaukos (GKOS)
Wedbush Reiterates Outperform on Inozyme Pharma, Maintains $15 Price Target
Inozyme Pharma Analyst Ratings
Inozyme Pharma Analyst Ratings
HC Wainwright & Co. Reiterates Buy on Inozyme Pharma, Maintains $14 Price Target
Buy Rating Affirmed for Inozyme Pharma Amid Promising Drug Developments and Strong Revenue Projections
Inozyme Pharma Analyst Ratings
Inozyme Pharma Inc: Wells Fargo launches insurance with an increase in holdings rating; target price is $14
Inozyme Pharma Buy Rating Affirmed on Strong Trial Results and Robust Pipeline Prospects
Inozyme Pharma Analyst Ratings